- Home
- LSBK vs BDTX Comparison
LSBK vs BDTX Comparison
Compare LSBK & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | BDTX |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 116.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSBK | BDTX |
|---|---|---|
| Price | $15.95 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 4.4K | ★ 881.5K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | 49.23 | ★ 130.71 |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.50 | $1.68 |
| 52 Week High | $16.28 | $4.94 |
Technical Indicators
Market Signals| Indicator | LSBK | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 58.23 |
| Support Level | $14.57 | $2.45 |
| Resistance Level | $16.28 | $3.04 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 33.36 | 53.50 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.